Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Narrative (Details)

v3.10.0.1
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended 15 Months Ended 48 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2018
Dec. 31, 2018
Disaggregation of Revenue [Line Items]                          
Prior period performance obligation revenue recognized                 $ 22,800,000 $ 66,000,000.0      
Overpayments received period         10 years                
Overpayment reimbursement liability $ 35,900,000       $ 30,000,000.0       35,900,000 30,000,000.0   $ 35,900,000 $ 35,900,000
Revenue recognized                       0  
Total revenues 221,852,000 $ 249,815,000 $ 263,685,000 $ 254,914,000 160,983,000 $ 246,040,000 $ 292,601,000 $ 266,382,000 990,266,000 966,006,000 $ 1,117,494,000    
Contract liability 91,100,000       $ 152,300,000       91,100,000 152,300,000   91,100,000 91,100,000
Rayaldee                          
Disaggregation of Revenue [Line Items]                          
Revenue recognized                 20,300,000 9,100,000      
Total revenues                 36,715,000        
Transfer Of Intellectual Property And Other                          
Disaggregation of Revenue [Line Items]                          
Total revenues                 69,906,000 75,537,000 105,455,000    
Pfizer | Collaborative Arrangement, Product                          
Disaggregation of Revenue [Line Items]                          
Revenue recognized                         0
Contract liability $ 83,100,000               83,100,000     $ 83,100,000 $ 83,100,000
Pfizer | Collaborative Arrangement, Product | Transfer Of Intellectual Property And Other                          
Disaggregation of Revenue [Line Items]                          
Total revenues                 60,000,000.0 61,200,000 47,300,000    
Tesaro | Collaborative Arrangement, Product                          
Disaggregation of Revenue [Line Items]                          
Revenue recognized                 0 $ 10,000,000.0 0    
Vifor Fresenius Medical Care Pharma Ltd | Collaborative Arrangement, Product | Transfer Of Intellectual Property And Other                          
Disaggregation of Revenue [Line Items]                          
Total revenues                 $ 2,000,000.0        
Vifor Fresenius Medical Care Pharma Ltd | Development and License Agreement | Transfer Of Intellectual Property And Other                          
Disaggregation of Revenue [Line Items]                          
Total revenues                     $ 50,000,000.0